Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus GRISACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus GRISACTIN.
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER vs GRISACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death. At high concentrations, it may also directly damage fungal membranes.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
200 mg IV loading dose, then 100-200 mg IV once daily; for invasive candidiasis, 800 mg IV loading dose then 400 mg IV once daily.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function; prolonged to 98 hours in end-stage renal disease, requiring dose adjustment.
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 11% is excreted as metabolites in urine; fecal excretion accounts for less than 5%.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Category C
Category C
Antifungal
Antifungal